Scotia Capital Inc. Has $33.08 Million Stock Holdings in Thermo Fisher Scientific Inc. (NYSE:TMO)

Scotia Capital Inc. increased its stake in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 57.3% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 63,585 shares of the medical research company’s stock after buying an additional 23,168 shares during the period. Scotia Capital Inc.’s holdings in Thermo Fisher Scientific were worth $33,082,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. CenterBook Partners LP boosted its position in Thermo Fisher Scientific by 273.8% during the 4th quarter. CenterBook Partners LP now owns 1,327 shares of the medical research company’s stock worth $690,000 after acquiring an additional 972 shares during the last quarter. DRW Securities LLC bought a new stake in Thermo Fisher Scientific in the 4th quarter valued at $1,154,000. APG Asset Management US Inc. bought a new position in Thermo Fisher Scientific during the 4th quarter worth $4,107,000. Texas Yale Capital Corp. increased its position in Thermo Fisher Scientific by 7.7% during the 4th quarter. Texas Yale Capital Corp. now owns 530 shares of the medical research company’s stock worth $276,000 after buying an additional 38 shares during the period. Finally, Martingale Asset Management L P boosted its stake in shares of Thermo Fisher Scientific by 6.3% during the fourth quarter. Martingale Asset Management L P now owns 8,910 shares of the medical research company’s stock valued at $4,635,000 after purchasing an additional 528 shares in the last quarter. 89.23% of the stock is owned by institutional investors.

Thermo Fisher Scientific Stock Up 7.9 %

Shares of NYSE:TMO opened at $452.24 on Thursday. The stock has a market cap of $170.61 billion, a price-to-earnings ratio of 27.36, a P/E/G ratio of 2.99 and a beta of 0.86. The company has a 50 day moving average of $516.75 and a 200-day moving average of $541.75. The company has a debt-to-equity ratio of 0.59, a current ratio of 1.66 and a quick ratio of 1.29. Thermo Fisher Scientific Inc. has a one year low of $409.85 and a one year high of $627.88.

Thermo Fisher Scientific (NYSE:TMO) last announced its quarterly earnings data on Thursday, January 30th. The medical research company reported $6.10 EPS for the quarter, topping analysts’ consensus estimates of $5.94 by $0.16. Thermo Fisher Scientific had a net margin of 14.78% and a return on equity of 17.51%. On average, sell-side analysts forecast that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current year.

Thermo Fisher Scientific Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, April 15th. Stockholders of record on Friday, March 14th will be issued a $0.43 dividend. The ex-dividend date of this dividend is Friday, March 14th. This represents a $1.72 dividend on an annualized basis and a dividend yield of 0.38%. This is a boost from Thermo Fisher Scientific’s previous quarterly dividend of $0.39. Thermo Fisher Scientific’s dividend payout ratio is 10.41%.

Analyst Upgrades and Downgrades

A number of equities research analysts have weighed in on the company. UBS Group lifted their target price on Thermo Fisher Scientific from $700.00 to $715.00 and gave the stock a “buy” rating in a report on Friday, January 31st. Bank of America dropped their price target on Thermo Fisher Scientific from $675.00 to $660.00 and set a “buy” rating on the stock in a research report on Friday, December 13th. Sanford C. Bernstein upgraded Thermo Fisher Scientific from a “market perform” rating to an “outperform” rating and set a $630.00 target price for the company in a research note on Friday, January 10th. Wells Fargo & Company raised their price target on Thermo Fisher Scientific from $660.00 to $680.00 and gave the company an “overweight” rating in a report on Friday, January 31st. Finally, Scotiabank raised their price target on Thermo Fisher Scientific from $605.00 to $650.00 and gave the stock a “sector perform” rating in a research report on Monday, February 3rd. Four analysts have rated the stock with a hold rating and nineteen have issued a buy rating to the stock. Based on data from MarketBeat, Thermo Fisher Scientific presently has a consensus rating of “Moderate Buy” and a consensus price target of $653.23.

Insider Transactions at Thermo Fisher Scientific

In other news, CFO Stephen Williamson sold 9,825 shares of the firm’s stock in a transaction that occurred on Tuesday, February 4th. The shares were sold at an average price of $585.59, for a total transaction of $5,753,421.75. Following the completion of the sale, the chief financial officer now owns 27,296 shares of the company’s stock, valued at $15,984,264.64. This trade represents a 26.47 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this link. Also, SVP Michael A. Boxer sold 3,775 shares of the stock in a transaction on Monday, March 10th. The stock was sold at an average price of $532.52, for a total value of $2,010,263.00. Following the completion of the transaction, the senior vice president now owns 10,816 shares in the company, valued at approximately $5,759,736.32. This represents a 25.87 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 23,900 shares of company stock valued at $13,106,062. 0.34% of the stock is currently owned by insiders.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.